Roivant CEO, bullish on internal growth, dodges M&A chatternews2026-03-13T19:12:27+00:00March 13th, 2026|Endpoints News|
Gubra plots Roivant-like model as partnered obesity drugs take flightnews2026-03-13T15:21:57+00:00March 13th, 2026|Endpoints News|
Immutep’s LAG-3 drug fails Phase 3 lung cancer studynews2026-03-13T15:00:10+00:00March 13th, 2026|Endpoints News|
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia diseasenews2026-03-13T14:18:51+00:00March 13th, 2026|Endpoints News|
Y-mAbs terminates radiopharma trial; GSK gets expanded use for Arexvynews2026-03-13T13:48:06+00:00March 13th, 2026|Endpoints News|
Flagship startup loses CEO to Ipsen; Ionis to shed nearly six decades of board experiencenews2026-03-13T11:00:13+00:00March 13th, 2026|Endpoints News|
Grail names new CEO as Bob Ragusa retiresnews2026-03-13T03:23:06+00:00March 13th, 2026|Endpoints News|
Pfizer to close Ignite, its R&D services unit for small biotechsnews2026-03-12T16:22:55+00:00March 12th, 2026|Endpoints News|
A simpler form of DNA may be key to non-viral gene therapy, study suggestsnews2026-03-12T15:31:55+00:00March 12th, 2026|Endpoints News|
Biotech startups use funding extensions to sidestep full capital roundsnews2026-03-12T15:20:55+00:00March 12th, 2026|Endpoints News|
